Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.

"Transparency declarations: M.R.H. was an employee of Amplyx (now a Pfizer Inc. subsidiary). M.R.H. was previously an employee of Pfizer and holds Pfizer stock and is currently a consultant for Pfizer. O.A.C. reports: grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer and Scynexis; consulting fees from AbbVie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis and Seres; honoraria for lectures from Abbott, AbbVie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, Medscape, med update, Merck/MSD, Mylan, Noscendo, Pfizer and Shionogi; payment for expert testimony from Cidara; participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi and The Prime Meridian Group; a patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); stocks from Core Consulting; and honoraria from Novartis, AstraZeneca, Cerus, Vifor and Vertex. H.O. reports: consulting fees from MSD, Novartis, AstraZeneca, Grifols, SOBI, argenx, UCB, Servier and Pfizer; and was part of an independent data monitoring committee (IDMC) at Johnson & Johnson. D.T. reports: research grants from Deutsche Krebshilfe, Gilead, JOGU Mainz and Wilhelm-Sander-Stifung; honoraria from AAEF Rheinland-Pfalz, ACI Clinical, Akademie für Infektionsmedizin, AstraZeneca, BioNTech, Gilead, F2G, iQone, LAEK Hessen, MSD, Noscendo, Octapharma, Pfizer, Takeda and Tillotts; has been a consultant to ACI Clinical, BioNTech, German Society for Haematology and Medical Oncology (DGHO), Gilead, iQone, MSD, NCO, Noscendo, Octapharma, Pfizer, Sanofi and Takeda; and travel grants from AbbVie, Astellas, Cellgene, DGHO, German Society for Internal Medicine (DGIM), Gilead, Jazz, Medac, Paul Ehrlich Society (PEG) and Tillotts. P.K. reports: grants or contracts from German Federal Ministry of Research and Education (BMBF) Bundesweites Forschungsnetz Angewandte Surveillance und Testung (B-FAST) and Nationales Pandemie Kohorten Netz (NAPKON), German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; consulting fees from Ambu GmbH, Gilead Sciences, Mundipharma Research Limited, Noxxon N.V. and Pfizer Pharma; honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, Bio-Rad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, med update GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; participation on an Advisory Board for Ambu GmbH, Gilead Sciences, Mundipharma Research Limited and Pfizer Pharma; a pending patent currently being reviewed at the German Patent and Trade Mark Office; and other non-financial interests from Elsevier, Wiley and Taylor & Francis Online outside the submitted work. M.T. is a Pfizer employee and holds Pfizer stock. W.G.K. is an employee of Kramer Consulting LLC. E.L. and S.B. have no conflicts of interest to declare."

"Funding Financial support was provided by Amplyx Pharmaceuticals, Inc., now a subsidiary of Pfizer Inc., for conducting these studies and preparing the manuscript."